Patents by Inventor José Miguel Vela Hernández

José Miguel Vela Hernández has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
    Patent number: 11419873
    Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: August 23, 2022
    Assignee: WEX MEDICAL LIMITED
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
  • USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY
    Publication number: 20210252004
    Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
    Type: Application
    Filed: February 10, 2020
    Publication date: August 19, 2021
    Applicant: Wex Medical Limited
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
  • Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
    Patent number: 10624896
    Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 21, 2020
    Assignee: Wex Medical Limited
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
  • USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY
    Publication number: 20190160074
    Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 30, 2019
    Applicant: Wex Medical Limited
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
  • USE OF SIGMA RECEPTOR LIGANDS IN CANCER
    Publication number: 20190142840
    Abstract: The invention relates to compounds of general formula (I) having pharmacological activity towards the sigma receptor, for use in decreasing cancer cells proliferation and improving chemotherapeutic drug efficacy.
    Type: Application
    Filed: June 5, 2017
    Publication date: May 16, 2019
    Inventors: Daniel ZAMANILLO-CASTANEDO, José-Carlos PRADOS-SALAZAR, Sebastiá VIDELA-CÉS, José-Miguel VELA-HERNÁNDEZ, Carlos-Ramón PLATA-SALAMAN, Jordi BRUNA-ESCUER
  • 1-ARYL-3-AMINOALKOXY PYRAZOLES AS SIGMA LIGANDS ENHANCING ANALGESIC EFFECT OF OPIOIDS AND ATTENUATING THE DEPENDENCY THEREOF
    Publication number: 20190010128
    Abstract: The invention relates to the use of a group of sigma receptor ligands of formula (I) for the potentiation of the analgesic effect of opioids and opiates and at the same time for decreasing the dependency induced by them.
    Type: Application
    Filed: February 1, 2018
    Publication date: January 10, 2019
    Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela-Hernandez, Daniel Zamanillo-Castanedo
  • Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
    Patent number: 10149852
    Abstract: The present disclosure describes the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogs/derivatives as well as their acceptable salts, for treating neuropathic pain resulting from chemotherapy. Methods, compositions, dose units and dose forms of tetrodotoxin related to the use are described.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: December 11, 2018
    Assignee: WEX PHARMACEUTICALS INC.
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens, Susan Lu, Donald Wong, Walter Korz
  • 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
    Patent number: 9914705
    Abstract: The invention relates to the use of a group of sigma receptor ligands of formula (I) for the potentiation of the analgesic effect of opioids and opiates and at the same time for decreasing the dependency induced by them.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: March 13, 2018
    Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela-Hernandez, Daniel Zamanillo-Castanedo
  • SIGMA LIGANDS FOR POTENTIATING THE ANALGESIC EFFECT OF OPIOIDS AND OPIATES IN POST-OPERATIVE PAIN AND ATTENUATING THE DEPENDENCY THEREOF
    Publication number: 20180021309
    Abstract: The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (1) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.
    Type: Application
    Filed: August 3, 2017
    Publication date: January 25, 2018
    Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: José Miguel VELA HERNANDEZ, Daniel ZAMANILLO-CASTANEDO
  • Sigma ligands for use in the prevention and/or treatment of post-operative pain
    Patent number: 9844516
    Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: December 19, 2017
    Assignee: Laboratorios De Dr. Esteve
    Inventors: José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Margarita Puig Riera de Conias
  • Use of sigma ligands in opioid-induced hyperalgesia
    Patent number: 9789115
    Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: October 17, 2017
    Assignee: Laboratorios Del Dr. Esteve, S.A.
    Inventors: José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Margarita Puig Riera de Conias
  • Use of sigma ligands in diabetes type-2 associated pain
    Patent number: 9789117
    Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat type-2 diabetes-associated pain and related symptoms.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: October 17, 2017
    Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Jose Miguel Vela Hernandez, Maria Isabel Martin Fontelles
  • Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
    Patent number: 9782483
    Abstract: The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: October 10, 2017
    Assignee: Laboratories Del Dr. Esteve, S.A.
    Inventors: José Miguel Vela Hernández, Xavier Codony-Soler, Daniel Zamanillo-Castanedo
  • USE OF SIGMA RECEPTOR LIGANDS IN OSTEOARTHRITIS
    Publication number: 20170273948
    Abstract: The invention relates to compounds of formula (I) or formula (II) having pharmacological activity towards the sigma receptor, for use in the treatment or prevention of osteoarthritis and pain due to osteoarthritis.
    Type: Application
    Filed: December 15, 2015
    Publication date: September 28, 2017
    Inventors: José Miguel VELA HERNÁNDEZ, Manuel MERLOS-ROCA, Daniel ZAMANILLO-CASTANEDO
  • Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
    Patent number: 9757358
    Abstract: The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (I) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: September 12, 2017
    Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: José Miguel Vela Hernández, Daniel Zamanillo-Castanedo
  • USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY
    Publication number: 20170112829
    Abstract: The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.
    Type: Application
    Filed: January 10, 2017
    Publication date: April 27, 2017
    Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: José Manuel Baeyens-Cabrera, Helmut H. Buschmann, José-Miguel Vela-Hernandez, Daniel Zamanillo-Castanedo, Francisco Rafael Nieto-López
  • USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY
    Publication number: 20170000797
    Abstract: The present disclosure describes the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for treating neuropathic pain resulting from chemotherapy. Methods, compositions, dose units and dose forms of tetrodotoxin related to the use are described.
    Type: Application
    Filed: September 16, 2016
    Publication date: January 5, 2017
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens, Susan Lu, Donald Wong, Walter Korz
  • Sigma Ligands For the Prevention or Treatment of Pain Induced by Chemotherapy
    Publication number: 20160220575
    Abstract: The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.
    Type: Application
    Filed: April 7, 2016
    Publication date: August 4, 2016
    Applicant: Laboratorios del Dr. Esteve, S.A.
    Inventors: José Manuel Baeyens-Cabrera, Helmut Heinrich Buschmann, José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Francisco-Rafael Nieto-López
  • Sigma Ligands For the Prevention or Treatment of Pain Induced by Chemotherapy
    Publication number: 20160199380
    Abstract: The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.
    Type: Application
    Filed: March 17, 2016
    Publication date: July 14, 2016
    Applicant: Laboratorios del Dr. Esteve, S.A.
    Inventors: José Manuel Baeyens-Cabrera, Helmut Heinrich Buschmann, José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Francisco-Rafael Nieto-López
  • USE OF SIGMA RECEPTOR LIGANDS FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED TO INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS)
    Publication number: 20160151377
    Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS).
    Type: Application
    Filed: June 25, 2014
    Publication date: June 2, 2016
    Inventors: José Miguel VELA HERNÁNDEZ, Manuel MERLOS-ROCA, José-Manuel BAEYENS-CABRERA, Cruz-Miguel CENDÁN-MARTÍNEZ